€ 0.88
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.
Data is available to registered users only